Search Results
Sep 04, 2026, 08:26 ET COLLPLANT APPOINTS DR. RUTI BEN SHLOMI TO ITS BOARD OF DIRECTORS FOLLOWING CLOSING OF LIGHTSOLVER ACQUISITION
CollPlant Biotechnologies Ltd. (Nasdaq: CLGN) today announced the appointment of Dr. Ruti Ben Shlomi, Chief Executive Officer and Co-Founder of
More news about: CollPlant
Sep 03, 2026, 08:00 ET COLLPLANT COMPLETES ACQUISITION OF LIGHTSOLVER, ENTERING THE PHOTONIC COMPUTING SECTOR
Sept. 3, 2026 /PRNewswire/ -- CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) today announced the successful closing of its previously announced acquisition of LightSolver Ltd.
More news about: CollPlant
Sep 01, 2026, 16:01 ET COLLPLANT ANNOUNCES REVERSE SHARE SPLIT
REHOVOT, Israel, Sept. 1, 2026 /PRNewswire/ -- CollPlant Biotechnologies Ltd. (Nasdaq: CLGN) ("CollPlant" or the "Company"), today announced that its Board of Directors has approved a one-for-ten reverse share split of the Company's ordinary
More news about: CollPlant Ltd
Aug 31, 2026, 08:40 ET COLLPLANT IS ACQUIRING LIGHTSOLVER- ENTERS SUPERCOMPUTING AND PHOTONIC COMPUTING MARKETS
Aug. 31, 2026 /PRNewswire/ -- CollPlant Biotechnologies Ltd. (Nasdaq: CLGN) today announced that it has signed a definitive agreement to acquire LightSolver Ltd.
More news about: CollPlant
Jun 30, 2026, 08:00 ET COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.6 MILLION PRIVATE PLACEMENT
REHOVOT, Israel, June 30, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue
More news about: CollPlant
May 29, 2026, 07:00 ET COLLPLANT BIOTECHNOLOGIES REPORTS 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
REHOVOT, Israel, May 29, 2026 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and medical aesthetics company developing innovative technologies and products based on its non-animal-derived recombinant human collagen
More news about: CollPlant
Apr 13, 2026, 07:00 ET CollPlant Issues Letter to Shareholders
April 13, 2026 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary plant-derived recombinant human
More news about: CollPlant
Mar 26, 2026, 08:30 ET COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
REHOVOT, Israel, March 26, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived rhCollagen for tissue
More news about: CollPlant
Mar 24, 2026, 16:01 ET CollPlant Biotechnologies Receives Nasdaq Notification Regarding Minimum Bid Requirement
REHOVOT, Israel, March 24, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen)
More news about: CollPlant
Mar 18, 2026, 09:00 ET CollPlant Biotechnologies Launches Redesigned Corporate Website
REHOVOT, Israel, March 18, 2026 /PRNewswire/ -- CollPlant (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary plant-derived recombinant human
More news about: CollPlant
Mar 11, 2026, 08:00 ET COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FULL YEAR 2025 FINANCIAL RESULTS
March 11, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for medical
More news about: CollPlant
Feb 26, 2026, 08:00 ET CollPlant Biotechnologies Announces Korean Patent Allowance Secured for its Photocurable Dermal Filler
Feb. 26, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen
More news about: CollPlant
Feb 23, 2026, 07:00 ET CollPlant Elevates rhCollagen 3D Bioprinting Portfolio with Launch of Ready-to-Print BioFlex
ReproducibilityREHOVOT, Israel, Feb. 23, 2026 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen)
More news about: CollPlant
Feb 17, 2026, 07:00 ET CollPlant Targets New Aesthetic Market Driven by GLP-1 Weight-Loss Treatments
Feb. 17, 2026 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen),
More news about: CollPlant
Feb 05, 2026, 08:00 ET COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.0 MILLION REGISTERED DIRECT OFFERING
REHOVOT, Israel, Feb. 5, 2026 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue
More news about: CollPlant
Nov 26, 2025, 07:30 ET COLLPLANT BIOTECHNOLOGIES REPORTS 2025 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
REHOVOT, Israel, Nov. 26, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue
More news about: CollPlant
Nov 18, 2025, 07:00 ET COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2025 THIRD QUARTER FINANCIAL RESULTS
REHOVOT, Israel, Nov. 18, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue
More news about: CollPlant
Oct 27, 2025, 07:01 ET CollPlant Expands its rhCollagen Distribution Capabilities in the United States and Canada
REHOVOT, Israel, Oct. 27, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen),
More news about: CollPlant
Oct 20, 2025, 07:00 ET CollPlant's rhCollagen-Based BioInk Demonstrates Strong Performance Compared to Matrigel® in Study Conducted by Technion - Israel Institute of Technology
REHOVOT, Israel, Oct. 20, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen),
More news about: CollPlant
Oct 16, 2025, 07:00 ET First-in-Kind Fully Humanized 3D Bioprinted Human Skin Model Developed by Mayo Clinic Researchers using CollPlant's rhCollagen-Based BioInk
REHOVOT, Israel, Oct. 16, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing disruptive technologies and products based on its proprietary, non-animal recombinant human
More news about: CollPlant
Sep 30, 2025, 07:00 ET CollPlant Biotechnologies Announces Positive Results from non-clinical Studies of its Photocurable Regenerative Dermal and Soft Tissue Filler
REHOVOT, Israel, Sept. 30, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing disruptive technologies and products based on its proprietary non-animal recombinant human
More news about: CollPlant
Sep 15, 2025, 07:00 ET CollPlant Expands the Distribution of its VergenixSTR Product in Europe
Israel, Sept. 15, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), or 'CollPlant', a regenerative and aesthetics medicine company developing innovative
More news about: CollPlant